CD8A and hepatocellular carcinoma: Additionally, our experiments on hepa1-6 HCC bearing mice showed that combining Efm with sorafenib resulted in enhanced anti-tumor activity by increasing the fraction of tumor-infiltrating IFN-γ+CD8+ T cells.